OCUL Stock Cash Flow Statements

Ocular Therapeutix Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Ocular Therapeutix Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30

cash flows from operating activities:
net income	-67,814,000	-64,053,000	-48,388,000	-36,493,000	-43,777,000	-64,848,000	-29,220,000	-516,000	-20,682,000	-30,318,000	-15,542,000	-24,188,000	-18,766,000	-12,542,000	-3,850,000	2,657,000	-8,481,000	3,121,000	-85,612,000	-11,944,000	-36,568,000	-21,512,000	-26,017,000	-18,778,000	-24,453,000	-17,124,000	-17,399,000	-15,010,000	-13,804,000	-13,765,000		-15,567,000	-18,694,000	-16,023,000		-9,596,000	-11,445,000	-10,840,000	-10,637,000	-11,524,000	-10,009,000	-7,578,000	-7,954,000	-7,294,000
adjustments to reconcile net income to net cash from operating activities
stock-based compensation expense	9,678,000	10,456,000	7,197,000	6,641,000	11,293,000	7,978,000	4,328,000	4,512,000	4,413,000	4,572,000	4,234,000	4,240,000	4,281,000	4,209,000	3,841,000	3,758,000	4,292,000	3,086,000	2,104,000	1,936,000	1,826,000	1,665,000	1,953,000	3,169,000	1,695,000	1,942,000	1,949,000	1,873,000	1,830,000	1,831,000		1,750,000	1,757,000	1,705,000		1,369,000	1,515,000	1,349,000	1,336,000	1,231,000	1,152,000	921,000	977,000	607,000
non-cash interest expense	708,000	1,436,000	576,000	621,000	569,000	1,968,000	1,553,000	2,072,000	1,253,000	1,228,000	1,237,000	1,225,000	1,205,000	1,186,000	1,188,000	1,158,000	1,150,000	1,132,000	1,136,000	1,123,000	1,108,000	1,048,000	1,214,000	1,051,000	1,009,000	409,000	132,000	80,000	87,000	98,000		99,000	100,000	110,000		35,000	36,000	35,000	54,000	38,000	37,000	37,000	37,000	41,000
change in fair value of derivative liabilities	641,000	978,000	-623,000	-7,076,000	3,027,000	5,152,000	6,478,000
depreciation and amortization expense	1,026,000	981,000	951,000	959,000	956,000	920,000	958,000	890,000	652,000	483,000	491,000	509,000	552,000	557,000	570,000	594,000	611,000	646,000	667,000	665,000	707,000	734,000	674,000	669,000	598,000	589,000	582,000	573,000	566,000	565,000		482,000	354,000	261,000		216,000	207,000	205,000	200,000	194,000	187,000	173,000
gain on disposal of items of property and equipment
loss on extinguishment of debt					0	27,950,000																																					0	0
changes in operating assets and liabilities:
accounts receivable	-5,191,000	7,167,000	-2,153,000	-3,000	-3,686,000	-367,000	-2,590,000	3,720,000	-6,185,000	201,000	-1,523,000	680,000	2,725,000	-2,072,000	-1,583,000	-818,000	-5,103,000	-1,379,000	-4,473,000	-4,905,000	555,000	-881,000	-1,434,000	-499,000	-339,000	-75,000	39,000	45,000	-115,000	56,000		-67,000	33,000	6,000		-20,000	4,000	-34,000	-4,000	-25,000	188,000	-23,000	-276,000	7,000
prepaid expenses and other current assets	1,049,000	3,934,000	-306,000	-7,035,000	1,550,000	128,000	-2,932,000	-269,000	153,000	-718,000	-710,000	483,000	869,000	81,000	-874,000	940,000	-817,000	650,000	-2,322,000	-270,000	407,000	-234,000	-18,000	81,000	86,000	-667,000	-642,000	151,000	34,000	197,000		1,095,000	579,000	-1,167,000		7,000	572,000	305,000	267,000	429,000	-919,000	170,000	318,000	-305,000
inventory	230,000	-229,000	-635,000	142,000	27,000	-269,000	-48,000	-53,000	62,000	-292,000	-429,000	-45,000	-142,000	-108,000	-28,000	-110,000	11,000	78,000	-47,000	-87,000	40,000	-153,000	-59,000	-133,000	-497,000	-48,000	-115,000			-17,000		-37,000	6,000	17,000		23,000	-22,000	7,000	13,000	-2,000	13,000	-25,000	-16,000	-8,000
accounts payable	1,731,000	7,000	112,000	297,000	-2,420,000	1,693,000	656,000	247,000	-1,345,000	1,025,000	-1,122,000	1,310,000	304,000	-1,113,000	366,000	175,000	-268,000	1,523,000	-565,000	899,000	-550,000	-236,000	92,000	-742,000	13,000	761,000	207,000	536,000	-877,000	-662,000		-2,759,000	2,263,000	659,000		173,000	-541,000	79,000	708,000	-1,011,000	498,000	153,000	444,000	-282,000
operating lease assets	-55,000	117,000	-273,000	311,000	54,000	413,000					-4,038,000	301,000	287,000	275,000	262,000	249,000	239,000	227,000	218,000	207,000			181,000
accrued expenses	2,841,000	-5,145,000	4,206,000	5,603,000	7,860,000	-14,031,000	-1,246,000	2,597,000	2,050,000	-2,628,000	1,937,000	1,653,000	1,102,000	-3,048,000	188,000	2,601,000	2,039,000	-1,111,000	1,400,000	2,777,000	751,000	-2,617,000
deferred revenue	-64,000	-64,000	-62,000	-79,000	-62,000	-59,000	-124,000	-131,000	842,000	-160,000	-173,000	-53,000	-122,000	1,311,000																						0	0	-42,000	-41,000	-42,000	-125,000	62,000
operating lease liabilities	11,000	-256,000	-31,000	-447,000	-193,000	-515,000					3,923,000	-416,000	-398,000	-380,000	-361,000	-348,000	-333,000	-316,000	-300,000	-288,000	-277,000	-260,000	-248,000	-286,000	-64,000	-246,000
net cash from operating activities	-55,238,000	-44,671,000	-39,429,000	-36,559,000	-24,802,000	-33,887,000	-22,454,000	-7,732,000	-20,075,000	-19,973,000	-16,958,000	-13,169,000	-10,876,000	-18,600,000	-15,153,000	-12,982,000	-20,056,000	-17,359,000	-6,246,000	-13,658,000	-14,796,000	-18,854,000	-19,467,000	-19,544,000	-19,181,000	-19,386,000	-13,648,000	-10,873,000	-12,233,000	-12,473,000		-14,382,000	-11,131,000	-14,577,000		-7,331,000	-9,802,000	-9,256,000	-8,636,000	-9,700,000	-8,528,000	-6,879,000	-5,626,000	-6,333,000
capex	-1,686,000	-1,369,000	-157,000	-56,000	-1,091,000	137,000	-710,000	-108,000	-2,520,000	-2,733,000	-1,243,000	-562,000	-373,000	-153,000	-649,000	-85,000	-131,000	-148,000	-233,000	-206,000	-83,000	-228,000	-851,000	-220,000	-404,000	-549,000	-522,000	-364,000	-768,000	-80,000		-2,991,000	-3,716,000	-667,000		-923,000	-243,000	-18,000	-848,000	458,000	-746,000	-349,000	-441,000	-321,000
free cash flows	-56,924,000	-46,040,000	-39,586,000	-36,615,000	-25,893,000	-33,750,000	-23,164,000	-7,840,000	-22,595,000	-22,706,000	-18,201,000	-13,731,000	-11,249,000	-18,753,000	-15,802,000	-13,067,000	-20,187,000	-17,507,000	-6,479,000	-13,864,000	-14,879,000	-19,082,000	-20,318,000	-19,764,000	-19,585,000	-19,935,000	-14,170,000	-11,237,000	-13,001,000	-12,553,000		-17,373,000	-14,847,000	-15,244,000		-8,254,000	-10,045,000	-9,274,000	-9,484,000	-9,242,000	-9,274,000	-7,228,000	-6,067,000	-6,654,000
cash flows from investing activities:
purchases of property and equipment	-1,245,000	-1,933,000	-202,000	-89,000	-742,000	-255,000	-459,000	-259,000	-1,990,000	-3,379,000	-2,150,000	-794,000	-495,000	-276,000	-631,000	-276,000	-129,000	-158,000	-253,000	-214,000	-125,000	-249,000	-601,000	-419,000	-493,000	-725,000	-479,000	-473,000	-556,000	-381,000		-2,036,000	-3,998,000	-1,654,000		-869,000	-243,000	-127,000	-473,000	-76,000	-875,000	-354,000	-441,000	-274,000
proceeds from sales of property and equipment
net cash from investing activities	-1,115,000	-1,933,000	-202,000	-89,000	-742,000	-255,000	-459,000	-259,000	-1,990,000	-3,379,000	-2,150,000	-794,000	-495,000	-276,000	-631,000	-276,000	-129,000	-158,000	-253,000	-214,000	-125,000	-249,000	-601,000	-419,000	-493,000	-725,000	-479,000	-473,000	-556,000	-381,000		969,000	18,702,000	7,846,000		11,317,000	11,757,000	24,873,000	-2,086,000	-27,587,000	8,958,000	-17,854,000	-37,767,000	-274,000
cash flows from financing activities:
proceeds from exercise of stock options	3,068,000	4,183,000	3,989,000	4,178,000	1,704,000	4,870,000	8,000	62,000	403,000	78,000	0	374,000	11,000	129,000	172,000	679,000	538,000	1,197,000	1,541,000	538,000	378,000	128,000	44,000	33,000	0	1,000	51,000	73,000	7,000	266,000		141,000	36,000	2,000
proceeds from issuance of common stock pursuant to employee stock purchase plan			524,000	0			433,000	0			458,000	0			495,000	0			397,000	0			157,000	0			178,000	0				0							101,000	0
proceeds from issuance of common stock upon public offering, net of issuance costs							107,729,000	708,000								0	0	-275,000
proceeds from issuance of common stock and pre-funded warrants upon private placement, net of issuance costs			0	0	0	316,353,000
net cash from financing activities	97,806,000	4,183,000	4,513,000	4,178,000	2,196,000	321,223,000	108,170,000	51,935,000	9,645,000	78,000	458,000	374,000	493,000	129,000	667,000	679,000	2,667,000	-1,162,000	163,913,000	220,000	51,063,000	12,818,000	9,091,000	18,612,000	5,338,000	42,300,000	16,328,000	11,373,000	6,712,000	34,227,000		1,529,000	796,000	28,477,000		78,000	3,000	-189,000	308,000	-201,000	65,733,000	-137,000	-106,000	67,555,000
net increase in cash, cash equivalents and restricted cash	41,453,000	-42,421,000	-35,118,000	-32,470,000	-23,348,000	287,081,000	85,257,000								-15,117,000	-12,579,000			157,415,000	-13,652,000	36,142,000	-6,285,000	-10,977,000	-1,351,000	-14,336,000	22,189,000	2,201,000	27,000	-6,077,000	21,373,000
cash, cash equivalents and restricted cash at beginning of period	0	393,716,000	0	0	0	197,571,000	0	0	0	104,064,000	0	0	0	165,928,000	0	0	0	229,821,000	0	0	0	56,201,000	0	0	0	60,676,000	0	0	0	43,152,000
cash, cash equivalents and restricted cash at end of period	41,453,000	351,295,000	-35,118,000	-32,470,000	-23,348,000	484,652,000	85,257,000	43,944,000	-12,420,000	80,790,000	-18,650,000	-13,589,000	-10,878,000	147,181,000	-15,117,000	-12,579,000	-17,518,000	211,142,000	157,415,000	-13,652,000	36,142,000	49,916,000	-10,977,000	-1,351,000	-14,336,000	82,865,000	2,201,000	27,000	-6,077,000	64,525,000
supplemental disclosure of cash flow information:
cash paid for interest	2,308,000	2,140,000	3,335,000	2,603,000	2,628,000	12,967,000	2,599,000	1,344,000	820,000	701,000	626,000	531,000	495,000	495,000	489,000			593,000				585,000										387,000							309,000	317,000	315,000	310,000
supplemental disclosure of non-cash investing and financing activities:
additions to property and equipment included in accounts payable and accrued expenses	-441,000	564,000	45,000	33,000	-349,000	392,000	-251,000	151,000	-530,000	646,000	907,000	232,000	122,000	123,000																						-54,000								-47,000
receivable from exercise of stock options included in prepaid expenses and other current assets
gains and losses on extinguishment of debt			0				0
gain on disposal of property and equipment							2,000	0	0	-1,000					0
proceeds from issuance of short-term bridge loan							0	0	0	2,000,000
proceeds from issuance of barings notes payable							0
payments of debt refinancing costs
repayment of midcap notes payable							0
repayment from issuance of short-term bridge loan
proceeds from issuance of notes payable															0	0																0	0	3,700,000
payments of debt financing costs
issuance costs from the issuance of common stock upon public offering in prior period
repayment of notes payable															0	0	-2,084,000	-2,083,000									-1,543,000	-1,543,000	-1,542,000	-1,029,000		0	0	-1,300,000
repayment of short-term bridge loan							0	0	0	-2,000,000
operating lease assets and liabilities								111,000	-157,000	72,000
change in fair value of derivative liability									-1,131,000	6,563,000	-5,243,000	1,133,000	-2,773,000	-6,958,000	-15,872,000	-23,837,000	-13,396,000	-25,016,000	69,549,000	-3,771,000	17,007,000	3,404,000	3,024,000	-5,717,000	1,606,000	-3,223,000
net decrease in cash, cash equivalents and restricted cash									-12,420,000	-23,274,000	-18,650,000	-13,589,000	-10,878,000	-18,747,000				-18,679,000
proceeds from the paycheck protection program loan																			0	0
repayment of the paycheck protection program loan																			0	0
issuance costs from the issuance of common stock upon public offering
public offering costs included in accounts payable and accrued expenses at balance sheet dates																											31,000	-9,000	-265,000	285,000				55,000
loss on disposal of property and equipment												-1,000	0	2,000																													0	0
proceeds from issuance of 2026 convertible notes, net of issuance costs																							0	0	-70,000	37,345,000
additional right of use asset and related lease liability																							0	0
additions to property and equipment included in accounts payable and accrued expenses at balance sheet dates															-18,000	191,000	-2,000	10,000	20,000	8,000	42,000	21,000	-250,000	199,000	89,000	176,000	-43,000	109,000	-212,000	301,000								109,000
cashless exercise of warrant
derivative liability in connection with issuance of 2026 convertible notes																							0	1,749,000	0	14,685,000
proceeds from issuance of common stock upon public offering																			161,975,000	-318,000	50,335,000	12,690,000
(gain)/loss on disposal of property and equipment																							0																0	0
amortization of operating lease asset																										187,000
right of use asset																						188,000
purchase of premium on marketable securities																																							-313,000	-50,000	8,000	17,000
amortization of premium on marketable securities																																0	6,000	11,000		20,000	49,000	104,000	96,000	148,000	21,000	18,000
accrued expenses and deferred rent																							1,171,000	1,412,000	1,022,000	-1,891,000	1,599,000	850,000	38,000	-776,000		627,000	2,465,000	-153,000		446,000	-165,000	-424,000	-315,000	914,000	424,000	-804,000	850,000	654,000
proceeds from sale of property and equipment																																							0	0
purchases of marketable securities																																0	0	-3,000,000
proceeds from maturities of marketable securities
proceeds from issuance of common stock offering																							8,890,000	18,579,000	5,114,000	4,954,000	5,610,000	12,843,000	8,128,000	34,990,000		1,585,000	800,000	26,272,000
payments of insurance costs financed by a third party																																-197,000	-197,000	-197,000
non-cash operating lease costs
insurance premium financed by a third party																																							0
cash from operating activities
cash from investing activities
cash from financing activities
net increase in cash and cash equivalents																															-9,627,000	-11,884,000	8,367,000	21,746,000	-19,298,000	4,064,000	1,958,000	15,428,000	-10,414,000	-37,488,000			-43,499,000	60,948,000
change in restricted cash																																				0
maturities of marketable securities
cash and cash equivalents at beginning of period																																0	0	32,936,000		0	0	30,784,000	0	0	0	37,393,000	0	0
cash and cash equivalents at end of period																																-11,884,000	8,367,000	54,682,000		4,064,000	1,958,000	46,212,000	-10,414,000	-37,488,000	66,163,000	12,523,000	-43,499,000	60,948,000
additions to property and equipment included in accounts payable at balance sheet dates																																-955,000	282,000	987,000					-375,000	534,000	129,000	5,000
maturities of investments																																	22,700,000	12,500,000		14,684,000	25,000,000	25,000,000		30,000,000
purchases of investments																																				-2,500,000				-57,511,000	0	-17,500,000
proceeds from exercise of common stock options																																				78,000	70,000	5,000		31,000	110,000	34,000		4,000
proceeds from issuance of public offerings
payments of insurance costs financed by a third-party																																				0	-195,000	-194,000	-222,000	-198,000	-171,000	-171,000	-171,000
purchase of (premium) discount on marketable securities
proceeds from issuance common stock pursuant to employee stock purchase plan
deferred offering costs included in accounts payable and accrued expenses																																												-989,000
purchase discount on marketable securities
licensing and consultant fees paid in common stock																																											0	0
revaluation of preferred stock warrants																																											0	108,000
accounts receivable from related party																																											1,000	0
proceeds from issuance of redeemable convertible preferred stock, net of issuance costs
proceeds from issuance of notes payable and preferred stock warrants
proceeds from issuance of public offering																																							564,000	-34,000
payments of offering costs
accretion of redeemable convertible preferred stock to redemption value
conversion of redeemable convertible preferred stock to common stock																																											0
conversion of warrants for redeemable convertible preferred stock to warrants for common stock																																											0
cashless exercise of warrants
initial public offering costs included in accounts payable
proceeds from issuance of notes payable and preferred stock warrants, net of issuance costs																																												0
repayments of notes payable																																												0
payments of initial public offering costs																																											-6,000	-1,905,000
fair value of preferred stock warrants at grant date																																												0
net decrease in cash and cash equivalents																																										-24,870,000
other assets
proceeds from sales or maturities of investments
proceeds from issuance of common stock																																											0
depreciation expense																																												139,000
accretion of redeemable convertible preferred stock to redemption values																																												0
prepaid expense included in accrued expense

We provide you with 20 years of cash flow statements for Ocular Therapeutix stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Ocular Therapeutix stock. Explore the full financial landscape of Ocular Therapeutix stock with our expertly curated income statements.

The information provided in this report about Ocular Therapeutix stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.